PittsburghV1, Main, Exploration, bibRecord, 005372

In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide

Identifieur interne : 005372 ( Main/Exploration ); précédent : 005371; suivant : 005373

In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide

Auteurs : Sam N. Rothstein [États-Unis] ; Kelly D. Huber [États-Unis] ; Nicolas Sluis-Cremer [États-Unis] ; Steven R. Little [États-Unis]

Source :

Antimicrobial agents and chemotherapy [ 0066-4804 ] ; 2014.

RBID : Pascal:14-0080488

Descripteurs français

Pascal (Inist)
- In vitro, Caractérisation, Forme libération contrôlée, Formulation, Forme pharmaceutique, Enfuvirtide, Antiviral, Antirétroviral.

English descriptors

KwdEn :
- Antiretroviral agent, Antiviral, Characterization, Controlled release form, Dosage form, Enfuvirtide, Formulation, In vitro.

Abstract

Although approved by the U.S. Food and Drug Administration, enfuvirtide is rarely used in combination antiretroviral therapies (cART) to treat HIV-1 infection, primarily because of its intense dosing schedule that requires twice-daily subcutaneous injection. Here, we describe the development of enfuvirtide-loaded, degradable poly(lactic-co-glycolic) acid microparticles that provide linear in vitro release of the drug over an 18-day period. This sustained-release formulation could make enfuvirtide more attractive for use in cART.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000D83
to stream PascalFrancis, to step Curation: 003826
to stream PascalFrancis, to step Checkpoint: 000737
to stream Main, to step Merge: 005660
to stream Main, to step Curation: 005372

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide</title>
<author><name sortKey="Rothstein, Sam N" sort="Rothstein, Sam N" uniqKey="Rothstein S" first="Sam N." last="Rothstein">Sam N. Rothstein</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Qrono, Inc.</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Huber, Kelly D" sort="Huber, Kelly D" uniqKey="Huber K" first="Kelly D." last="Huber">Kelly D. Huber</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Sluis Cremer, Nicolas" sort="Sluis Cremer, Nicolas" uniqKey="Sluis Cremer N" first="Nicolas" last="Sluis-Cremer">Nicolas Sluis-Cremer</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Little, Steven R" sort="Little, Steven R" uniqKey="Little S" first="Steven R." last="Little">Steven R. Little</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Qrono, Inc.</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Chemical Engineering, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Bioengineering, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Department of Immunology, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>The McGowan Institute for Regenerative Medicine,University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0080488</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0080488 INIST</idno>
<idno type="RBID">Pascal:14-0080488</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D83</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003826</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000737</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000737</idno>
<idno type="wicri:doubleKey">0066-4804:2014:Rothstein S:in:vitro:characterization</idno>
<idno type="wicri:Area/Main/Merge">005660</idno>
<idno type="wicri:Area/Main/Curation">005372</idno>
<idno type="wicri:Area/Main/Exploration">005372</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide</title>
<author><name sortKey="Rothstein, Sam N" sort="Rothstein, Sam N" uniqKey="Rothstein S" first="Sam N." last="Rothstein">Sam N. Rothstein</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Qrono, Inc.</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Huber, Kelly D" sort="Huber, Kelly D" uniqKey="Huber K" first="Kelly D." last="Huber">Kelly D. Huber</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Sluis Cremer, Nicolas" sort="Sluis Cremer, Nicolas" uniqKey="Sluis Cremer N" first="Nicolas" last="Sluis-Cremer">Nicolas Sluis-Cremer</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Little, Steven R" sort="Little, Steven R" uniqKey="Little S" first="Steven R." last="Little">Steven R. Little</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Qrono, Inc.</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Chemical Engineering, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Bioengineering, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Department of Immunology, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>The McGowan Institute for Regenerative Medicine,University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antimicrobial agents and chemotherapy</title>
<title level="j" type="abbreviated">Antimicrob. agents chemother.</title>
<idno type="ISSN">0066-4804</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antimicrobial agents and chemotherapy</title>
<title level="j" type="abbreviated">Antimicrob. agents chemother.</title>
<idno type="ISSN">0066-4804</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiretroviral agent</term>
<term>Antiviral</term>
<term>Characterization</term>
<term>Controlled release form</term>
<term>Dosage form</term>
<term>Enfuvirtide</term>
<term>Formulation</term>
<term>In vitro</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>In vitro</term>
<term>Caractérisation</term>
<term>Forme libération contrôlée</term>
<term>Formulation</term>
<term>Forme pharmaceutique</term>
<term>Enfuvirtide</term>
<term>Antiviral</term>
<term>Antirétroviral</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Although approved by the U.S. Food and Drug Administration, enfuvirtide is rarely used in combination antiretroviral therapies (cART) to treat HIV-1 infection, primarily because of its intense dosing schedule that requires twice-daily subcutaneous injection. Here, we describe the development of enfuvirtide-loaded, degradable poly(lactic-co-glycolic) acid microparticles that provide linear in vitro release of the drug over an 18-day period. This sustained-release formulation could make enfuvirtide more attractive for use in cART.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
<settlement><li>Pittsburgh</li>
</settlement>
<orgName><li>Université de Pittsburgh</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Rothstein, Sam N" sort="Rothstein, Sam N" uniqKey="Rothstein S" first="Sam N." last="Rothstein">Sam N. Rothstein</name>
</region>
<name sortKey="Huber, Kelly D" sort="Huber, Kelly D" uniqKey="Huber K" first="Kelly D." last="Huber">Kelly D. Huber</name>
<name sortKey="Little, Steven R" sort="Little, Steven R" uniqKey="Little S" first="Steven R." last="Little">Steven R. Little</name>
<name sortKey="Little, Steven R" sort="Little, Steven R" uniqKey="Little S" first="Steven R." last="Little">Steven R. Little</name>
<name sortKey="Little, Steven R" sort="Little, Steven R" uniqKey="Little S" first="Steven R." last="Little">Steven R. Little</name>
<name sortKey="Little, Steven R" sort="Little, Steven R" uniqKey="Little S" first="Steven R." last="Little">Steven R. Little</name>
<name sortKey="Little, Steven R" sort="Little, Steven R" uniqKey="Little S" first="Steven R." last="Little">Steven R. Little</name>
<name sortKey="Sluis Cremer, Nicolas" sort="Sluis Cremer, Nicolas" uniqKey="Sluis Cremer N" first="Nicolas" last="Sluis-Cremer">Nicolas Sluis-Cremer</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005372 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005372 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:14-0080488
   |texte=   In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide

In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri